Suppr超能文献

米托坦和垂体照射使库欣病持续缓解。

Sustained remission of Cushing's disease with mitotane and pituitary irradiation.

作者信息

Schteingart D E, Tsao H S, Taylor C I, McKenzie A, Victoria R, Therrien B A

出版信息

Ann Intern Med. 1980 May;92(5):613-9. doi: 10.7326/0003-4819-92-5-613.

Abstract

Low doses of mitotane were given orally to 36 patients with Cushing's disease, concurrently with or after pituitary cobalt irradiation. Clinical and biochemical remission occurred in 29. The response to treatment occurred early in 17 patients and late in 12. The different pattern of response to mitotane was not related to the dose given or to its serum level. Early biochemical indicators of adrenal suppression with mitotane were a sharp decrease in adrenal response to the infusion of ACTH and in plasma levels of dehydroepiandrosterone sulfate. Although mitotane was given together with pituitary irradiation, initial remission was due mainly to the adrenal effect of mitotane. Plasma ACTH levels were still elevated when cortisol had returned to normal. In seventeen of the 29 patients who responded to treatment drug therapy has been discontinued, and they remain in remission of Cushing's syndrome. Side-effects have been dose dependent, with anorexia, nausea, decreased memory, and gynecomastia in men being the commonest.

摘要

对36例库欣病患者口服低剂量的米托坦,同时或在垂体钴照射之后使用。29例实现了临床和生化缓解。17例患者治疗反应出现得早,12例出现得晚。对米托坦不同的反应模式与给药剂量或血清水平无关。米托坦引起肾上腺抑制的早期生化指标是肾上腺对促肾上腺皮质激素输注的反应以及硫酸脱氢表雄酮血浆水平急剧下降。虽然米托坦与垂体照射同时使用,但最初的缓解主要归因于米托坦的肾上腺效应。当皮质醇恢复正常时,血浆促肾上腺皮质激素水平仍升高。在29例对治疗有反应的患者中,17例已停用药物治疗,他们仍处于库欣综合征缓解状态。副作用具有剂量依赖性,最常见的是厌食、恶心、记忆力减退和男性乳腺增生。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验